Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Dec 6;134(23):1909-1911.
doi: 10.1161/CIRCULATIONAHA.116.025257.

Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers

Lori A Gordon  1 , Parag Kumar  2 , Kristina M Brooks  1 , Anela Kellogg  1 , Maryellen McManus  1 , Raul M Alfaro  1 , Khanh Nghiem  1 , Jomy M George  1 , Jay Lozier  1 , Scott R Penzak  1 , Colleen Hadigan  1
Affiliations
Clinical Trial

Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers

Lori A Gordon et al. Circulation. .
No abstract available

Keywords: anticoagulants; antiretroviral; cobicistat; dabigatran; drug-drug interaction; pharmacodynamics; pharmacokinetics; thrombin time.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mean (±SEM) dabigatran plasma concentration (A) and Median (90% CI) thrombin time (B) after administration of dabigatran alone, administration separated by 2 hours, and simultaneously with cobicistat (COBI).
See this image and copyright information in PMC

References

    1. Saber AA, Aboolian A, LaRaja RD, Baron H, Hanna K. HIV/AIDS and the risk of deep vein thrombosis: a study of 45 patients with lower extremity involvement. Am Surg. 2001;67:645–647. - PubMed
    1. Marzolini C, Gibbons S, Khoo S, Back D. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016 Mar 5; - PubMed
    1. Hartter S, Sennewald R, Nehmiz G, et al. Oral bioavailability of dabigatran etexilate (Pradaxa®) after co-medication with verapamil in healthy participants. British Journal of Clinical Pharmacology. 2013;75:1053–1062. - PMC - PubMed
    1. Kis O, Sankaran-Walters S, Hoque MT, Walmsley SL, Dandekar S, Bendayan R. HIV-1 alters intestinal expression of drug transporters and metabolic enzymes: implications for antiretroviral drug disposition. Antimicrob Agents Chemother. 2016;60:2771–2781. - PMC - PubMed
    1. Perram J, Joseph J, Holloway C. Novel oral anticoagulants and HIV: dabigatran use with antiretrovirals. BMJ Case Rep. 2015 - PMC - PubMed

MeSH terms